Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: A stochastic league approach

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages 221-228

  Nichols, Brooke E ^a   Baltussen, Rob ^b   Van Dijk, Janneke H ^c   Thuma, Phil E ^c   Nouwen, Jan L ^a   Boucher, Charles A B ^a   Van De Vijver, David A M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Macha Mission Hospital   (Zambia)

Author keywords

cost effectiveness; pre exposure prophylaxis; stochastic league tables; treatment as prevention

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BUDGET; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INVESTMENT; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RURAL AREA; STOCHASTIC MODEL; ZAMBIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; PREVALENCE; ZAMBIA;

EID: 84901491559     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000145     Document Type: Conference Paper

References (40)

1. UNAIDS. World AIDS Day Report 2012. Geneva, Switzerland: UNAIDS; 2012.
2. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
4. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
8. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
9. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
10. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013.
11. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2013.
12. Rosen S, Fox MP. Retention HIV care between testing treatment Sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.
13. Kranzer K, Govindasamy D, Ford N, et al. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2012;15:17383.
14. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
15. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
16. Topp SM, Li MS, Chipukuma JM, et al. Does provider-initiated counselling and testing (PITC) strengthen early diagnosis and treatment initiation? Results from an analysis of an urban cohort of HIV-positive patients in Lusaka, Zambia. J Int AIDS Soc. 2012;15:17352.
17. Nichols BE, Boucher CA, van Dijk JH, et al. Cost-effectiveness preexposure prophylaxis (PrEP) preventing HIV-1 infections rural Zambia: a model study. PloS One. 2013;8:e59549.
18. Murnane PM, Celum C, Mugo N, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from the Partners PrEP Study. AIDS. 2013;27(13):2155-2160.
19. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Geneva, Switzerland: World Health Organization; 2011. Available at: http://www.who.int/ choice/costs/en/. Accessed December 1, 2011.
20. PEPFAR. Fiscal year 2011: PEPFAR operational plan. Washington, DC: PEPFAR; 2011.
21. van Dijk JH, Sutcliffe CG, Munsanje B, et al. Barriers to the care of HIVinfected children in rural Zambia: a cross-sectional analysis. BMC Infect Dis. 2009;9:169.
22. UNAIDS/WHO. Epidemiological Fact Sheet on HIV and AIDS. Core Data on Epidemiology and Response. Zambia. Geneva, Switzerland: UNAIDS; 2008.
23. van de Vijver DA, Nichols BE, Abbas UL, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2942-2951.
24. Rose KA, Smith EP, Gardner RH, et al. Parameter sensitivities, Monte Carlo Filtering, and model forecasting under uncertainty. J Forecast. 1991;10:117-133.
25. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25:473-477.
26. The World Bank. Zambia: World Development Indicators. Washington, DC: The World Bank; 2013. Available at: http://data.worldbank.org/country/zambia. Accessed May 2, 2013.
27. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, New York: Oxford University Press; 2005.
28. Hutubessy RC, Baltussen RM, Evans DB, et al. Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ. 2001;10:473-477. (Pubitemid 32755275)
29. Lord J, Asante MA. Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Health Econ. 1999;8:323-333. (Pubitemid 29346924)
30. Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9: 235-251. (Pubitemid 30248640)
31. Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. Laryngoscope. 2013;123(6):1341-1347.
32. Cremin I, Alsallaq R, Dybul M, et al. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27:447-458.
33. Abbas UL, Glaubius R, Mubayi A, et al: Combined impact on HIV-1 transmission and drug resistance in South Africa. J Infect Dis. 2013;208 (2):224-234.
34. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLos One. 2007;2:e875.
35. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of preexposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504-1513.
36. Williams BG, Abdool Karim SS, Karim QA, et al. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr. 2011;58:207-210.
37. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses antiretrovirals prevention HIV-1 serodiscordant heterosexual couples South Africa: a modelling study. PLoS Med. 2011;8:e1001123.
38. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLos One. 2010;5:e13646.
39. Gomez GB, Borquez A, Case KK, et al. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10:e1001401.
40. Nichols BE, Sigaloff KC, Kityo C, et al. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS. 2014;28(1):73-83.